Premal Thaker, MD, MS

Gynecologic Oncology, Surgeon

Premal Thaker

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Center for Advanced Medicine

Center for Advanced Medicine

On WashU Medicine Campus
4921 Parkview Place, Saint Louis, MO 63110

Expertise & Training

Video thumbnail for Premal Thaker, MD, MS

Watch video on YouTube

Premal Thaker, MD, MS

3 mins

Washington University surgeon Premal Thaker, MD, MS, discusses what gynecologic cancer patients can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Thaker: https://siteman.wustl.edu/doctor/premal-thaker-md-ms/

Learn more about the Gynecologic Oncology Program at Siteman: https://siteman.wustl.edu/treatment/specialized-programs/gynecologic-oncology/

Almost all cervical cancers are caused by the human papillomavirus (HPV). Here's what you need to know about the link between HPV and cervical cancer: https://siteman.wustl.edu/facts-about-hpv-cervical-cancer/

Symptoms of ovarian cancer can be easy to miss. Learn about what signs to look out for: https://siteman.wustl.edu/subtle-signs-of-ovarian-cancer-women-should-look-out-for/

Endometrial cancer is the 4th most common cancer in women in the U.S., but it's highly curable when caught early. Learn more about the risk factors, symptoms and screening: https://siteman.wustl.edu/endometrial-cancer-symptoms/

Clinical Expertise

  • As a member of our ovarian, cervical and endometrial cancer specialist teams, Dr.Thaker cares for patients diagnosed with these cancers through treatment and recovery.

Primary Academic Title

David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology; Chief, Division of Gynecologic Oncology; Director, Gynecological Oncology Clinical Research

Training

  • 1997-1999: Intern and resident, Obstetrics and Gynecology, Allegheny University Hospital-City Avenue, Philadelphia, PA
  • 1999-2002: Resident, Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA
  • 2002-2006: Fellow, Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX

Education

  • 1997: MD, Medical College of Pennsylvania, Philadelphia, PA
  • 2004: MS, Cancer Biology, University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research & Selected Publications

Biobehavioral influences on cancer development and therapy in gynecologic malignancies.

Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings
Authors:

Thaker PH, Lindborg SR, Limon A, one or more additional authors omitted Alvarez RD

Journal & Year:

Expert Opin Investig Drugs | 2026

Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma
Authors:

Furuya RL, Grither W, Evans MG, one or more additional authors omitted Thaker PH

Journal & Year:

Gynecol Oncol | 2026

Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the US
Authors:

Thaker PH, Lu H, Zhang YJ, one or more additional authors omitted Ting J

Journal & Year:

Gynecol Oncol Rep | 2025

Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
Authors:

Valentine MC, Mullen MM, Kotnik EN, one or more additional authors omitted Thaker PH, one or more additional authors omitted Fuh KC

Journal & Year:

Cancer Res | 2025

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Authors:

Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, one or more additional authors omitted Thaker PH, one or more additional authors omitted Grisham RN

Journal & Year:

J Clin Oncol | 2025

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer
Authors:

Schab A, Compadre A, Drexler R, one or more additional authors omitted Thaker P, one or more additional authors omitted Mullen MM

Journal & Year:

J Clin Invest | 2025

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advance…
Authors:

Thaker PH, Richardson DL, Hagemann AR, one or more additional authors omitted Bradley WH

Journal & Year:

Gynecol Oncol | 2025

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Authors:

Eskander RN, Sill MW, Beffa L, one or more additional authors omitted Thaker PH, one or more additional authors omitted Aghajanian C

Journal & Year:

Nat Med | 2025